Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial

J Cassidy, J-Y Douillard, Chris Twelves, Joseph McKendrick, Werner Scheithauer, I Bustova, P G Johnston, K Lesniewski-Kmak, G Fountzilas, F Coxon, E Diaz-Rubio, T S Maughan, A Malzyner, O Bertetto, A Beham, A Figer, P Dufour, K K Patel, W Cowell, L P Garrison

Research output: Contribution to journalArticleResearchpeer-review

97 Citations (Scopus)
Original languageEnglish
Pages (from-to)1122 - 1129
Number of pages8
JournalBritish Journal of Cancer
Volume94
Publication statusPublished - 2006

Cite this

Cassidy, J., Douillard, J-Y., Twelves, C., McKendrick, J., Scheithauer, W., Bustova, I., Johnston, P. G., Lesniewski-Kmak, K., Fountzilas, G., Coxon, F., Diaz-Rubio, E., Maughan, T. S., Malzyner, A., Bertetto, O., Beham, A., Figer, A., Dufour, P., Patel, K. K., Cowell, W., & Garrison, L. P. (2006). Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial. British Journal of Cancer, 94, 1122 - 1129.